Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Trial Profile

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Samyang Biopharmaceuticals Corporation
  • Most Recent Events

    • 28 May 2013 Data was published for the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) and chosen for inclusion online in the ASCO 2013 Annual Meeting Proceedings, according to a Sorrento Therapeutics media release.
    • 13 May 2013 Status changed from active, no longer recruiting to completed, based on information in a Sorrento Therapeutics and IgDraSol media release.
    • 28 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top